Cambrex Reports Fourth Quarter and Full Year 2017 Financial Results

- Net Revenue increased 2.5% for the fourth quarter and 9% for the full year 2017-

- Conference call at 8:30 a.m. ET on February 8, 2018 -

EAST RUTHERFORD, N.J., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the fourth quarter and full year ended December 31, 2017.

Highlights

  • Net revenue increased 2.5% to $182.3 million compared to $177.9 million in the same quarter last year. Excluding the impact of foreign exchange, net revenue increased 1%. Full year net revenue increased 9% to $534.5 million, compared to $490.6 million in the full year 2016.
  • GAAP Diluted EPS from continuing operations increased 4% to $1.20 per share from $1.15 per share in the same quarter last year. Full year GAAP Diluted EPS from continuing operations increased 17% to $3.10 per share from $2.65 per share in the full year 2016.
  • EBITDA increased to $64.7 million compared to $63.6 million in the same quarter last year. Full year Adjusted EBITDA increased 13% to $174.6 million from $154.2 million in the full year 2016 (see table at the end of this release).
  • Net cash was $183.3 million at the end of the year, an increase of $64.9 million during the quarter and $109.1 million during the year.
  • The Company continued to execute on its strategic growth plan, investing in new manufacturing capacity and analytical laboratory space at its facilities in Charles City, Iowa, High Point, North Carolina, Karlskoga, Sweden and Milan, Italy.
  • The Company expects full year 2018 Adjusted net revenue, excluding the impact of foreign currency and change in accounting principle, to be between -2% and 2% compared to 2017 and Adjusted EBITDA to be between $150 and $160 million. (see Financial Expectations – Continuing Operations section below for related explanations and additional financial guidance).

“We are pleased with our strong financial performance in 2017, our seventh straight year of solid growth. The fourth quarter was a record revenue quarter with Net revenue up 2.5% compared to a record fourth quarter last year. Strong performance at our manufacturing facilities resulted in higher profit margins versus last year,” commented Steven M. Klosk, President and Chief Executive Officer of Cambrex.

“With our recently completed large scale manufacturing capacity projects and the on-going investments in R&D and pilot plant capabilities, we are well positioned to ensure our facilities are able to keep up with the strong market demand.”

Basis of Reporting

The Company has provided a reconciliation of GAAP amounts to adjusted (i.e. Non-GAAP) amounts at the end of this press release. Cambrex management believes that the adjusted amounts provide useful information to investors due to the magnitude and nature of certain expenses recorded in the GAAP amounts.

Fourth Quarter 2017 Operating Results – Continuing Operations

Net revenue was $182.3 million, an increase of $4.4 million, or 2.5%, compared to the fourth quarter of 2016. Excluding a 1.5% favorable impact of foreign exchange compared to the fourth quarter of 2016, net revenue increased 1%. The increase primarily reflects higher volumes in the generic and controlled substance product categories, partially offset by lower volumes and pricing of certain branded APIs.

Gross margin decreased to 43% from 45% compared to the same quarter last year. Excluding a 1% unfavorable impact of foreign exchange compared to the fourth quarter of 2016, margins were relatively flat year over year.

Selling, general and administrative expenses were $18.7 million, compared to $18.2 million in the same quarter last year. This increase was primarily due to higher expenses related to consulting for an operational excellence initiative.

Research and development expenses were $4.3 million, compared to $3.5 million in the same quarter last year. This increase was primarily driven by costs to develop new generic drug products and higher personnel related expenses.

Operating profit decreased to $55.9 million from $56.7 million in the same quarter last year. This decrease was primarily the result of higher operating expenses as described above.

Adjusted EBITDA was $64.7 million compared to $64.4 million in the same quarter last year (see table at the end of this press release).

Income tax expense was $15.6 million resulting in an effective tax rate of 28% compared to $18.4 million and an effective tax rate of 33% in the same quarter last year. The favorable impact of immediately recognizing certain effects of share-based compensation as required by a recently adopted accounting standard and the unfavorable impact of U.S. tax reform legislation enacted in December 2017, was negligible.

Income from continuing operations was $40.2 million or $1.20 per share compared to $37.9 million or $1.15 per share in the same quarter last year. Adjusted income from continuing operations was $42.4 million or $1.27 per share, compared to $40.8 million or $1.23 per share in the same quarter last year (see table at the end of this press release).

Capital expenditures and depreciation were $13.2 million and $8.3 million, respectively, compared to $11.9 million and $6.6 million, respectively, in the same quarter last year.

Net cash was $183.3 million at the end of the fourth quarter, an increase of $64.9 million during the quarter.

Financial Expectations – Continuing Operations

The following table shows the Company’s current expectations for its full year 2018 financial performance:

Expectations
Adjusted net revenue -2% - 2%
Adjusted EBITDA $150 - $160 million
Adjusted income from continuing operations per share $2.80 - $3.03
Free cash flow $35 - $45 million
Capital expenditures $70 - $80 million
Depreciation and amortization $33 - $37 million
Adjusted effective tax rate 23% - 25%

Consistent with the Company’s usual guidance practices, these financial expectations are for continuing operations and exclude the impact of any potential acquisitions, divestitures, restructuring activities, outcomes of tax disputes and the adoption of the new revenue recognition guidance effective January 1, 2018. Adjusted net revenue expectations exclude the impact of foreign exchange and change in accounting principle. EBITDA, Adjusted EBITDA and Adjusted income from continuing operations per share for 2018 will be computed on a basis consistent with the reconciliation of the 2017 financial results in the tables at the end of this press release. Free cash flow is defined as the change in debt, net of cash during the year. Adjusted effective tax rate excludes certain effects of share-based payments that were possibly deferred under the previous guidance. The tax rate will be sensitive to the Company’s geographic mix of income, changes in the tax laws or rates within the countries in which the Company operates and the effects of certain share-based payments.

The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company’s 2017 Form 10-K is filed with the SEC.

Conference Call and Webcast

A conference call to discuss the Company’s fourth quarter and full year 2017 results will begin at 8:30 a.m. Eastern Time on February 8, 2018 and can be accessed by calling 1-888-394-8218 for domestic and +1-323-701-0226 for international. Please use the passcode 9709552 and call approximately 10 minutes prior to the start time. A webcast will be available in the Investors section on the Cambrex website located at www.cambrex.com. A telephone replay of the conference call will be available through February 15, 2018 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international. Please use the passcode 9709552 to access the replay.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.

Forward-Looking Statements

This document contains “forward-looking statements,” including statements or tables regarding expected performance, especially those set forth under the heading “Financial Expectations – Continuing Operations,” “Highlights” and those attributed to the President and Chief Executive Officer in this document. These and other forward-looking statements may be identified by the fact that they use words such as “guidance,” “expects,” “anticipates,” “intends,” “estimates,” “believes” or similar expressions. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. The factors described in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the period ended December 31, 2016, and the Company’s Annual Report on Form 10-K for the period ended December 31, 2017, once filed with the SEC, captioned “Risk Factors,” or otherwise described in the Company’s filings with the SEC provide examples of such risks and uncertainties that may cause the Company’s actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, customer and product concentration, the Company’s ability to win new customer contracts and renew existing contracts on favorable terms, pharmaceutical outsourcing trends, competitive pricing or product developments, market acceptance and adoption rate of its customers’ products, government legislation and regulations (including those pertaining to environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, environmental matters, changes in foreign exchange rates, uncollectible receivables, the timing of orders or shipments and the Company’s ability to meet its production plan and customer delivery schedules, expected timing of completion of capacity expansions, our ability to successfully integrate acquired businesses, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company’s ability to receive regulatory approvals for its products, continued demand in the U.S. for late stage clinical products and the successful outcome of the Company’s investment in new products.

For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, once filed with the SEC, including the Forward-Looking Statement sections therein, and other filings with the SEC. The Company cautions investors and potential investors not to place undue reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in the Company’s SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

Use of Non-GAAP Financial Measures

Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations are non-GAAP financial measures. Adjusted net revenue excludes the change in an accounting principle related to revenue recognition and the Company defines EBITDA as operating profit plus depreciation and amortization expense and Adjusted EBITDA excludes the impact of any potential acquisitions, restructuring activities and any charges related to the sale of the Company’s Zenara business. Adjusted effective tax rate excludes certain effects of share-based payments that were possibly deferred under the previous guidance. Adjusted income from continuing operations is calculated in a manner consistent with that shown in the table at the end of this press release. Other companies may have different definitions of Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations. Therefore, these measures may not be comparable with non-GAAP financial measures provided by other companies. Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations should not be considered alternatives to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex’s liquidity. Cambrex uses Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations among several other metrics to assess and analyze its operational results and trends. Cambrex also believes Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations are useful to investors because they are common operating performance metrics as well as metrics routinely used to assess potential enterprise value. Cambrex has provided a reconciliation of U.S. GAAP amounts to non-GAAP amounts at the end of this press release.


CAMBREX CORPORATION
Statements of Profit and Loss
For the Quarters Ended December 31, 2017 and 2016
(in thousands, except per share data)
2017 2016
% of % of
Amount Net Revenue Amount Net Revenue
Gross Sales$ 175,505 $ 178,682
Commissions, Allowances and Rebates 527 468
Net Sales 174,978 178,214
Other Revenues/(Expense), Net 7,299 (348)
Net Revenue 182,277 177,866
Cost of Goods Sold 103,406 56.7% 98,699 55.5%
Gross Profit 78,871 43.3% 79,167 44.5%
Operating Expenses:
Selling, General and Administrative Expenses 18,683 10.2% 18,217 10.2%
Research and Development Expenses 4,311 2.4% 3,496 2.0%
Restructuring Expenses - 0.0% 761 0.4%
Total Operating Expenses 22,994 12.6% 22,474 12.6%
Operating Profit 55,877 30.7% 56,693 31.9%
Other Expenses/(Income):
Interest Expense, Net 262 360
Other Income, Net (211) (46)
Income Before Income Taxes 55,826 30.6% 56,379 31.7%
Provision for Income Taxes 15,577 18,430
Income from Continuing Operations$ 40,249 22.1% $ 37,949 21.3%
Income/(Loss) from Discontinued Operations, Net of Tax 10 (565)
Net Income$ 40,259 22.1% $ 37,384 21.0%
Basic Earnings/(Loss) per Share of Common Stock:
Income from Continuing Operations$ 1.23 $ 1.18
Income/(Loss) from Discontinued Operations, Net of Tax$ 0.00 $ (0.02)
Net Income$ 1.23 $ 1.16
Diluted Earnings/(Loss) per Share of Common Stock:
Income from Continuing Operations$ 1.20 $ 1.15
Income/(Loss) from Discontinued Operations, Net of Tax$ 0.00 $ (0.02)
Net Income$ 1.20 $ 1.13
Weighted Average Shares Outstanding
Basic 32,810 32,240
Diluted 33,532 33,107

CAMBREX CORPORATION
Statements of Profit and Loss
For the Twelve Months Ended December 31, 2017 and 2016
(in thousands, except per share data)
2017 2016
% of % of
Amount Net Revenue Amount Net Revenue
Gross Sales$ 525,936 $ 491,538
Commissions, Allowances and Rebates 1,995 2,369
Net Sales 523,941 489,169
Other Revenues, Net 10,515 1,475
Net Revenue 534,456 490,644
Cost of Goods Sold 304,369 56.9% 286,419 58.4%
Gross Profit 230,087 43.1% 204,225 41.6%
Operating Expenses:
Selling, General and Administrative Expenses 70,468 13.2% 60,422 12.3%
Research and Development Expenses 16,901 3.2% 14,292 2.9%
Restructuring Expenses - 0.0% 1,158 0.2%
Total Operating Expenses 87,369 16.3% 75,872 15.5%
Operating Profit 142,718 26.7% 128,353 26.2%
Other Expenses/(Income):
Interest Expense, Net 1,253 717
Other (Income)/Expense, Net (360) 97
Income Before Income Taxes 141,825 26.5% 127,539 26.0%
Provision for Income Taxes 38,061 40,214
Income from Continuing Operations$ 103,764 19.4% $ 87,325 17.8%
Loss from Discontinued Operations, Net of Tax (1,314) (5,647)
Net Income$ 102,450 19.2% $ 81,678 16.6%
Basic Earnings/(Loss) per Share of Common Stock:
Income from Continuing Operations$ 3.18 $ 2.72
Loss from Discontinued Operations, Net of Tax$ (0.04) $ (0.17)
Net Income$ 3.14 $ 2.55
Diluted Earnings/(Loss) per Share of Common Stock:
Income from Continuing Operations$ 3.10 $ 2.65
Loss from Discontinued Operations, Net of Tax$ (0.04) $ (0.17)
Net Income$ 3.06 $ 2.48
Weighted Average Shares Outstanding
Basic 32,662 32,086
Diluted 33,486 32,969

CAMBREX CORPORATION
Consolidated Balance Sheets
As of December 31, 2017 and December 31, 2016
(in thousands)
December 31, December 31,
Assets 2017 2016
Cash and Cash Equivalents$ 183,284 $ 74,141
Trade Receivables, Net 75,144 110,622
Other Receivables 20,891 6,748
Inventories, Net 138,542 123,184
Prepaid Expenses and Other Current Assets 4,217 7,960
Total Current Assets 422,078 322,655
Property, Plant and Equipment, Net 254,299 217,092
Goodwill 43,626 40,323
Intangible Assets, Net 13,868 14,800
Deferred Income Taxes 3,198 13,061
Other Non-Current Assets 3,496 3,934
Total Assets$ 740,565 $ 611,865
Liabilities and Stockholders' Equity
Accounts Payable$ 35,017 $ 42,873
Deferred Revenue and Advance Payments 4,707 7,506
Taxes Payable 43 9,469
Accrued Expenses and Other Current Liabilities 42,774 35,614
Total Current Liabilities 82,541 95,462
Advance Payments 39,000 39,000
Deferred Income Taxes 7,806 6,921
Accrued Pension Benefits 41,141 43,109
Other Non-Current Liabilities 25,213 21,946
Total Liabilities$ 195,701 $ 206,438
Stockholders’ Equity$ 544,864 $ 405,427
Total Liabilities and Stockholders’ Equity$ 740,565 $ 611,865

CAMBREX CORPORATION
Reconciliation of GAAP to non-GAAP Results
For the Quarters and Twelve Months Ended December 31, 2017 and 2016
(in thousands)
Fourth Quarter 2017 Fourth Quarter 2016
Operating Profit$55,877 $56,693
Depreciation and Amortization 8,825 6,948
EBITDA 64,702 63,641
Restructuring Expenses - 761
Adjusted EBITDA$64,702 $64,402
Twelve Months 2017 Twelve Months 2016
Operating Profit$142,718 $128,353
Depreciation and Amortization 31,848 24,665
EBITDA 174,566 153,018
Restructuring Expenses - 1,158
Adjusted EBITDA$174,566 $154,176

CAMBREX CORPORATION
Reconciliation of GAAP to non-GAAP Results
For the Quarters and Twelve Months Ended December 31, 2017 and 2016
(in thousands)
Fourth Quarter 2017 Fourth Quarter 2016
Diluted
EPS
Diluted
EPS
Income from Continuing Operations$ 40,249 $ 1.20 $ 37,949 $ 1.15
Stock-Based Compensation 2,593 0.08 2,577 0.08
Stock-Based Compensation Tax 1. (908) (0.03) (902) (0.03)
Impact of New Stock-Based Compensation Standard 2. (122) (0.00) - -
Amortization of Purchased Intangibles 503 0.02 397 0.01
Restructuring Expenses - - 761 0.02
Impact of U.S. Tax Reform 3. 117 0.00 - -
Adjusted Income from Continuing Operations 4.$ 42,432 $ 1.27 $ 40,782 $ 1.23
Twelve Months 2017 Twelve Months 2016
Diluted
EPS
Diluted
EPS
Income from Continuing Operations$ 103,764 $ 3.10 $ 87,325 $ 2.65
Stock-Based Compensation 8,914 0.27 7,766 0.24
Stock-Based Compensation Tax 1. (3,120) (0.09) (2,718) (0.08)
Impact of New Stock-Based Compensation Standard 2. (5,236) (0.16) - -
Amortization of Purchased Intangibles 1,878 0.06 1,011 0.03
Restructuring Expenses - - 1,158 0.04
Impact of U.S. Tax Reform 3. 117 0.00 - -
Adjusted Income from Continuing Operations 4.$ 106,317 $ 3.17 $ 94,542 $ 2.87
1. Tax rate estimated at 35% for stock-based compensation.
2. Represents a tax benefit resulting from the adoption of ASU 2016-09.
3. Represents tax expense resulting from the U.S. enactment of TCJA tax reform legislation, and a provisional one-time toll charge.
4. Diluted earnings per share for adjusted income from continuing operations is based on the weighted number of diluted shares outstanding for the quarter and year. As such, the sum of the quarters may not necessarily equal the full year. In addition, the sum of the line items may not equal due to rounding.

Contact:
Tom Vadaketh
Executive Vice President & CFO
Tel: +201.804.3033
Email: tom.vadaketh@cambrex.com

Source:Cambrex Corporation